<PAGE>

                      AGREEMENT FOR SALE AND PURCHASE OF ASSETS


    THIS AGREEMENT FOR SALE AND PURCHASE OF ASSETS ("Agreement") is made and
entered into effective as of this 28th day of May, 1997, by and among
INGENEX, INC., a Delaware corporation whose principal place of business is 1505
O'Brien Drive, Suite B, Menlo Park, California 94025 ("INGENEX"), SUBSIDIARY NO.
3, INC., a North Carolina corporation whose principal place of business is 3151
17th Street Extension, Wilmington, North Carolina 28412 ("SUBSIDIARY"), and
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC., a North Carolina corporation whose
principal place of business is 3151 17th Street Extension, Wilmington, North
Carolina  28412 ("PPD").

                                       RECITALS

    WHEREAS, INGENEX is the current owner of the GSX System, a genomics
platform technology used to identify genes based upon their functional roles in
a biological or disease process and to pinpoint key steps in a disease pathway
for therapeutic intervention (the "GSX System"); and

    WHEREAS, INGENEX desires to sell to SUBSIDIARY and SUBSIDIARY desires to
purchase the GSX System and all tangible and intangible assets, properties,
benefits and rights owned, used or useful in the operation of the business
related to the GSX System (the business and operations related to the GSX System
being referred to herein as the "Business"), upon and subject to the terms and
conditions set forth hereinafter.

                                      AGREEMENT

    NOW, THEREFORE, in consideration of the premises and the mutual promises
and covenants herein contained, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties, intending
to be legally bound, hereby agree as follows:

                                      ARTICLE 1
                                  ASSETS PURCHASED

    1.1  ACQUIRED ASSETS.  Upon and subject to the terms and conditions set
forth in this Agreement, on the Closing Date (as hereinafter defined) INGENEX
shall sell, assign, transfer and convey to SUBSIDIARY and SUBSIDIARY shall
purchase and acquire from INGENEX the GSX System and all tangible and intangible
properties, assets, benefits and rights owned, licensed (subject to the
limitations of such licenses) or used by or useful to INGENEX in the operation
of the GSX System and the Business (the "Acquired Assets").  The "Acquired
Assets" specifically include the following assets of INGENEX as the same shall
exist on the Closing Date:

<PAGE>

         1.1.1 The machinery, equipment, furniture, tools and fixtures of
INGENEX, used specifically in connection with the Business, wherever located,
and all warranties and claims pertaining thereto, as listed on SCHEDULE 1.1.1
attached hereto (the "Equipment").

         1.1.2 The inventory, laboratory supplies and materials,  and all other
tangible personal property of INGENEX of whatever sort or description used
specifically in connection with the Business (the "Inventory").

         1.1.3  All of INGENEX's rights, title and interest in and to and
benefits under the License Agreements used specifically in connection with the
Business listed on SCHEDULE 1.1.3 attached hereto (the "License Agreements").
License Agreements shall mean and include all of the following items: (i) all
licenses, sublicenses and other agreements as to which INGENEX is a party and
pursuant to which any person is authorized to use any of the Intellectual
Property (as hereinafter defined), and (ii) all licenses, sublicenses and other
agreements as to which INGENEX is a party and pursuant to which INGENEX is
authorized to use any third party patents, trademarks or copyrights, including
software, which are incorporated in, are, or form a part of any INGENEX product
or service that is material to the Business.

         1.1.4 All of INGENEX's rights, title and interest in and to and
benefits under that certain Lease dated March 6, 1996 between Menlo Business
Park and Patrician Associates, Inc. and INGENEX (the "Lease") and relating to
the real property (the "Premises") described in the Lease, and all of INGENEX's
leasehold improvements located on the Premises and any appurtenances thereto,
all as listed on SCHEDULE 1.1.4 attached hereto (the "Lease").  Notwithstanding
the foregoing sentence, INGENEX shall retain ownership of  the "clean room",
which shall be removed from the Premises by INGENEX at its sole expense within 
120 days after the Closing. INGENEX shall be responsible and pay for any damage
to the Premises resulting from the removal of the clean room.

         1.1.5  All patents, patent applications, copyrights, trademarks,
service marks and trade names, inventions, products, trade secrets, proof of
principle, product ideas, works of authorship, processes, copyrightable or
patentable materials, biological material (including cell lines, antibodies,
c-DNAs, antisense nucleotides, proteins, vectors, new chemical entities, media,
reagents and related materials) and any other proprietary information or
intellectual property (whether or not registered) presently owned, licensed or
assigned to INGENEX used in the operation of the GSX System or the Business (the
"Intellectual Property").  SCHEDULE 1.1.5 lists all patents and patent
applications and all registered and unregistered trademarks, trade names and
service marks, registered and unregistered copyrights, and mask works that are
included in the Intellectual Property, including the jurisdictions in which each
such Intellectual Property right has been issued or registered or in which any
application for such issuance and registration has been filed.

         1.1.6  All of INGENEX's rights, title and interest in and to and
benefits under the contracts, permits, agreements, purchase orders and leases,
whether oral or written, used specifically in connection with the Business, as
listed on SCHEDULE 1.1.6 attached hereto (the "Contracts").

         1.1.7  All prepaid expenses incurred in the ordinary course of
business as listed on SCHEDULE 1.1.7 attached hereto (the "Prepaid Expenses").


                                          2

<PAGE>

         1.1.8  Copies of all books, records, client lists, correspondence and
files, business forms, personnel records (to the extent permitted to be
transferred by applicable law) and other information and data in whatever form
recorded pertaining to the Business (the "Records").

         1.1.9  All claims, refunds, causes of action, choses in action, rights
of recovery, warranty rights, rights of offset and rights of recoupment of
INGENEX relating to the operation of the GSX System and the Business (the
"Deposits").

         1.1.10  All other intangible assets owned, used or useful in the
operation of the GSX System and the Business, together with all goodwill and
going concern value relating to the GSX System, the Business and the other
Acquired Assets (the "Goodwill"). 

    1.2  TRANSFER OF ACQUIRED ASSETS.  On the Closing Date (as hereinafter
defined), the Acquired Assets shall be conveyed to SUBSIDIARY by appropriate
transfer documents as follows:  (i) title to the Equipment, Inventory, Prepaid
Expenses, Records, Deposits and Goodwill shall be conveyed pursuant to a Bill of
Sale and Assignment in the form attached hereto as EXHIBIT 1.2A, (ii) title to
the License Agreements shall be conveyed pursuant to an Assignment and
Assumption of License Agreements in the form attached hereto as EXHIBIT 1.2B,
(iii) title to the Contracts shall be conveyed pursuant to an Assignment and
Assumption of Contracts in the form attached as EXHIBIT 1.2C, (iv) title to any
patents or patent applications shall be conveyed pursuant to an Assignment of
Patents and Patent Applications in the form attached hereto as EXHIBIT 1.2D, or
pursuant to such other transfer documents reasonably necessary to convey the
same to SUBSIDIARY, (v) title to the Intellectual  Property (other than patents
and patent applications) presently owned by or assigned to INGENEX shall be
conveyed pursuant to an Intellectual Property Assignment in the form attached
hereto as EXHIBIT 1.2E, and (vi) title to the Lease shall be conveyed pursuant
to an  Assignment, Assumption and Amendment of Lease in the form attached hereto
as EXHIBIT 1.2F.  

    1.3  TITLE TO ACQUIRED ASSETS. On the Closing Date, INGENEX shall deliver
to SUBSIDIARY good title to the Acquired Assets free and clear of any mortgages,
pledges, claims, liens, conditional sales or other agreements, leases,
encumbrances, rights, contracts or other charges of any nature (hereinafter
collectively referred to as "Liens and Encumbrances") other than such Liens and
Encumbrances that have been granted under or attach to the Acquired Assets with
respect to any of the Assumed Liabilities (as hereinafter defined) as set forth
in SCHEDULE 1.3 (the "Accepted Liens and Encumbrances").

    1.4  POSSESSION OF ACQUIRED ASSETS.  INGENEX shall deliver possession of
the  Acquired Assets to SUBSIDIARY at the Premises on the Closing Date.
Possession of the Premises shall be delivered to SUBSIDIARY on the Closing Date
free and clear of all claims, or rights of use or possession other than those
claims or rights created by SUBSIDIARY or PPD or as set forth in the Lease. 
 
                                      ARTICLE 2
                              PURCHASE PRICE AND PAYMENT

    2.1  PURCHASE PRICE. The purchase  price for the Acquired Assets (the
"Purchase Price") shall be Eight Million Seven Hundred Twenty-Two Thousand Five
Hundred Dollars


                                          3

<PAGE>

($8,722,500), which shall be paid by SUBSIDIARY to INGENEX at Closing by
confirmed wire transfer of funds on the Closing Date to the account designated
by INGENEX on SCHEDULE 2.1. 

    2.2  LIMITED ASSUMPTION OF LIABILITIES BY SUBSIDIARY.  On the Closing Date,
INGENEX shall assign to SUBSIDIARY and SUBSIDIARY shall assume, indemnify and
hold harmless INGENEX from any obligations under the License Agreements, the
Contracts and the Lease to the extent related to performance due on or after the
Closing Date (collectively, the "Assumed Liabilities").

    2.3  EXCLUDED LIABILITIES.  Except for the Assumed Liabilities, SUBSIDIARY
and PPD do not assume and shall not assume any debt, obligation, agreement,
contract, lease or any other liability whatsoever of INGENEX of any kind or
nature, absolute or contingent, known or unknown, incurred or arising out of
transactions or operation of the GSX System or the Business or of any other
business of INGENEX prior to the Closing Date (collectively, the "Excluded
Liabilities").  Without limiting the generality of the immediately preceding
sentence, the Excluded Liabilities to be retained by INGENEX shall include the
following:

         2.3.1     All liabilities and obligations of INGENEX to any third
party arising from the breach by INGENEX, prior to the Closing Date, of any
contract, including, without limitation, the License Agreements, the Contracts
and the Lease; 

         2.3.2     All liabilities and obligations of INGENEX for any federal,
state and local income, profits, franchise, capital stock, property, sales, use,
payroll, occupation, excise or other taxes, fees, duties, deficiencies,
assessments, withholdings or other governmental charges of any nature (including
interest, penalties or other additions thereto) (hereinafter, "Taxes"), except
to the extent such liabilities and obligations arise on or after the Closing
Date in connection with the operation of the Business by SUBSIDIARY after the
Closing Date;

         2.3.3     All liabilities and obligations of INGENEX in connection
with the violation of any foreign, federal, state or local law or regulation,
except to the extent such liabilities and obligations arise on or after the
Closing Date in connection with the operation of the Business by SUBSIDIARY
after the Closing Date;

         2.3.4     All liabilities and obligations of INGENEX to its 
collaborative scientific partners, customers, sponsors or other third parties as
a result of any act or omission or arising under any warranties (express or
implied) provided by INGENEX for goods and/or services provided prior to the
Closing Date; 

         2.3.5     All liabilities and obligations of INGENEX, except to the
extent such liabilities and obligations arise on or after the Closing Date in
connection with the operation of the Business by SUBSIDIARY after the Closing
Date for accrued (i) pension benefits, (ii) severance or termination benefits
and (iii) health, life and disability insurance premiums of the employees and
retirees of INGENEX; 

         2.3.6     INGENEX's liabilities to its employees for accrued payroll,
vacation and sick leave arising prior to the Closing Date; and


                                          4

<PAGE>

         2.3.7     All other liabilities and obligations arising out of or
connected with any employee benefit plan (as defined in Section 3(3) of the
Employee Retirement Income Security Act of 1974, as amended ("ERISA")),
maintained at any time by INGENEX or to which INGENEX ever made any
contributions. 

                                      ARTICLE 3
                                CLOSING DATE AND PLACE

    Provided that all conditions precedent to Closing shall have been satisfied
or waived by the appropriate party, the closing of the transactions contemplated
by this Agreement (the "Closing") shall occur on or before May 30, 1997 (the
"Closing Date"), or on such earlier or later date as may be set by mutual
agreement of the parties. The Closing shall occur at such place, time and
location and in such manner as is mutually acceptable to the parties.
Notwithstanding anything herein to the contrary, if the Closing has not occurred
on or before May 30, 1997 (except that if any of the conditions set forth in
Articles 8 or 9 Section 8.8.7, 8.8.12, 8.8.13, 8.8.14, 9.6.6 or 9.6.9 have not
been satisfied by May 30, 1997, then each party shall have until June 6, 1997 to
satisfy such conditions), then either INGENEX or PPD or SUBSIDIARY shall have
the right to terminate this Agreement, each by providing notice to the other,
whereupon, subject to the following, this Agreement shall become null and void
and of no further force or effect.  Notwithstanding the termination of this
Agreement, such termination shall be without prejudice to a party's rights and
remedies as a result of any breach or default on the part of another party. 

                                      ARTICLE 4
                                ADDITIONAL AGREEMENTS

    4.1  EMPLOYMENT AGREEMENTS WITH CERTAIN KEY EMPLOYEES.  Effective as of the
Closing Date, SUBSIDIARY shall enter into employment agreements with each of
Mark E. Furth, Ph.D. and Tatyana Holzmayer, Ph.D. in the form of EXHIBITS 4.1A
and 4.1B, respectively.

    4.2  CONSULTING AGREEMENTS WITH CERTAIN KEY PERSONS.  Effective as of the
Closing Date, INGENEX shall amend its existing Consulting Agreements dated May
20, 1992 between INGENEX (formerly Pharm-Gen Systems, Ltd.) and each of Igor
Roninson, Ph.D. and Richard L. Davidson, Ph.D. and its Scientific Advisory and
Consulting Agreement dated January 1, 1994 with Eli Gilboa, Ph.D., in each case
in form and substance satisfactory to each of the parties thereto and to PPD and
SUBSIDIARY.  Each of such amendments shall: (i) prohibit the consultant from
providing consulting services to INGENEX after the Closing with respect to the
GSX System or the Business, and (ii) provide that any consulting services
provided to PPD or SUBSIDIARY with respect to the GSX System or the Business
following the Closing shall not be considered violations of any of the
provisions of such Consulting Agreements.  Effective as of the Closing Date,
INGENEX shall terminate all consulting or similar agreements (oral or written)
with Andrei Gudkov, Ph.D.  Effective as of the Closing Date, SUBSIDIARY shall
enter into new consulting agreements with each of Andrei Gudkov, Ph.D. and Eli
Gilboa, Ph.D. in the form of EXHIBITS 4.2A and 4.2B, respectively. SUBSIDIARY
shall have the right (but not obligation) to negotiate and enter into new
consulting agreements with each of Igor Roninson, Ph.D. and Richard L. Davidson,
Ph.D. with respect to the GSX System and the Business upon such terms and
conditions which are mutually acceptable to the parties.

                                          5

<PAGE>

    4.3  OTHER EMPLOYEES.  SUBSIDIARY shall have the right to employ and shall
employ each of the employees of INGENEX identified on SCHEDULE 4.3 effective as
of the Closing Date; provided, however, that this Agreement shall not be
construed to create any contractual employment rights in any of such employees
hired by SUBSIDIARY other than as employees terminable at any time at will.  As
a condition of such employment by SUBSIDIARY, each employee must execute a
standard Proprietary Information and Inventions Agreement with and for the
benefit of SUBSIDIARY.

         4.4  NEW LEASE WITH PHOENIX CAPITAL.  With respect to the equipment
listed on SCHEDULE 4.4, effective on or before the Closing Date, INGENEX shall
have caused such equipment to be released from and no longer subject to any of
the provisions of that certain Master Equipment Lease dated February 15, 1994
(the "Current Lease") between Phoenix Leasing Incorporated ("Phoenix") and Titan
Pharmaceuticals, Inc. ("TITAN") and that certain Sublease and Acknowledgment of
Assignment dated February 15, 1994 between TITAN, INGENEX, Geneic Sciences,
Inc., Theracell, Inc. and Ansan, Inc. The form and substance of such releases
shall be reasonably satisfactory to PPD. SUBSIDIARY shall negotiate in good
faith for a new equipment lease with Phoenix, which equipment lease shall be
upon such terms and conditions reasonably satisfactory to SUBSIDIARY and PPD. 
PPD and SUBSIDIARY acknowledge that a new lease with terms and conditions
substantially similar to the Current Lease with respect to such equipment shall
be deemed reasonably satisfactory.

         4.5  GUARANTY OF LEASE BY PPD.  If required by the landlord as a
condition to assignment of the Lease to SUBSIDIARY and to the release of TITAN
from any obligations with respect to the Lease, PPD agrees to guarantee the
payment of rent under the Lease.  Any such guaranty required of PPD shall be
upon such terms and conditions as shall be reasonably satisfactory to PPD.  PPD
acknowledges that a guarantee substantially similar to that executed by TITAN in
connection with the Current Lease shall be deemed reasonably satisfactory.

         4.6  RELEASE OF  GSE LICENSE AGREEMENT FROM ABERLYN CAPITAL AGREEMENT. 
Effective prior to or as of the Closing Date, INGENEX shall cause that certain
GSE Exclusive License Agreement dated as of May 6, 1992 between The Board of
Trustees of the University of Illinois and INGENEX (formerly Pharm-Gen Systems,
Ltd.) to be released from and no longer subject to the provisions of the License
Assignment and License Agreement between INGENEX and Aberlyn Capital Management
Limited Partnership dated January 31, 1995 (as then in effect).  The form and
substance of such release shall be reasonably satisfactory to PPD.

         4.7  TERMINATION OF CERTAIN EMPLOYMENT AGREEMENTS. Effective as of the
Closing Date, INGENEX shall terminate the Employment Agreement between INGENEX
and Mark E. Furth, Ph.D. dated July 25, 1995 and shall release Mark E. Furth,
Ph.D. from any further liabilities or obligations thereunder, including
specifically any restrictive covenants related to the Business. Effective as of
the Closing Date, INGENEX shall terminate the Employment Agreement between
INGENEX and Tatyana Holzmayer, Ph.D. dated August 9, 1993 and shall release
Tatyana Holzmayer, Ph.D. from any further liabilities or obligations thereunder,
including specifically any restrictive covenants related to the Business. 

         4.8  RELEASE FROM PROPRIETARY INFORMATION AGREEMENTS.  Effective as of
the Closing Date, INGENEX shall release each of Mark E. Furth, Ph.D. and Tatyana
Holzmayer, Ph.D. from their respective Proprietary Information and Inventions
Agreement, dated July 25, 1995 and


                                          6

<PAGE>

August 9, 1993, respectively, to the extent that such agreements relate to the
GSX System, the Business or the Acquired Assets. Effective as of the Closing
Date, INGENEX shall release each employee listed on SCHEDULE 4.3 who is hired by
either PPD or SUBSIDIARY from their respective Proprietary Information and
Inventions Agreements to the extent that such agreements relate to the GSX
System, the Business or the Acquired Assets.  All such releases hereunder shall
be in the form of EXHIBIT 4.8 attached hereto. 

    4.9  ALLOCATION OF PURCHASE PRICE.  By mutual agreement of the parties, the
total consideration payable hereunder for the Acquired Assets (which comprises
the Purchase Price and the value of all Assumed Liabilities) shall be allocated
among the various Acquired Assets pursuant to SCHEDULE 4.9 to be prepared by the
parties and attached as of Closing.  The allocations will be made by SUBSIDIARY
in a manner reasonably acceptable to INGENEX and consistent with the residual
method of accounting.  SUBSIDIARY and INGENEX agree that the allocation set
forth in SCHEDULE 4.9 shall be used by them for all tax purposes, including, but
not limited to, reporting pursuant to Section 1060 of the Code.  In preparing
and filing IRS Form 8594 ("Asset Acquisition Statement Under Section 1060"),
SUBSIDIARY and INGENEX shall report that the allocation of consideration set
forth herein and the fair market value of the assets to which such consideration
is allocated is the same.  Prior to filing Form 8594 with respect to the
transaction described herein, INGENEX and SUBSIDIARY shall provide to one
another a true and correct copy of the Form 8594 which each intends to file with
respect to this transaction.

    4.10 BULK SALES LAWS.  PPD and SUBSIDIARY hereby waive compliance by
INGENEX with the provisions of any applicable state bulk transfer statutes and
INGENEX covenants and agrees to pay and discharge when due all claims of
creditors asserted against either PPD or SUBSIDIARY or any of their affiliates
by reason of any failure of INGENEX to so comply, and to indemnify PPD and
SUBSIDIARY and its affiliates fully in respect thereof, which indemnity shall
survive Closing.

    4.11 ADJUSTMENTS.  Rent, real estate taxes, water, sewer, and other current
lienable charges, if any, relating to the Premises shall be apportioned as of
the Closing Date on the basis of the fiscal year of the taxing body or the
period covered by such charges.  INGENEX shall be responsible for any benefit
assessments assessed or levied against the Premises prior to the Closing Date. 
PPD shall be responsible for any benefit assessments assessed or levied against
the Premises on or after the Closing Date.  The security deposit of Twenty-Seven
Thousand Two Hundred Twelve and 40/100 Dollars ($27,212.40) that INGENEX has
paid to the landlord pursuant to the Lease shall be treated as a prepaid item
for which SUBSIDIARY shall reimburse INGENEX at Closing in exchange for
assignment to SUBSIDIARY of all of INGENEX's rights and interests in the
security deposit. 

    4.12 REALTY TRANSFER TAX.  INGENEX shall pay any realty transfer taxes
required to be paid as a result of the conveyance of the Lease to SUBSIDIARY.

    4.13 NON-COMPETITION AGREEMENT OF INGENEX.  At Closing, INGENEX shall
execute a certain non-competition agreement (the "Non-Competition Agreement") in
the form attached hereto as EXHIBIT 4.13. 

    4.14 POST-CLOSING ACCESS TO RECORDS. Following the Closing Date, INGENEX
shall provide PPD or SUBSIDIARY during normal business hours reasonable access
to and shall permit


                                          7

<PAGE>

either of them to make reasonable numbers of copies of financial records and
other information related to operation of the GSX System and the Business prior
to the Closing (to the extent that such records or other information exists) for
the purpose of preparing audited financial statements covering any period prior
to the Closing Date and for such other purposes as PPD or SUBSIDIARY may
reasonably request from time to time.  Following the Closing Date, PPD and
SUBSIDIARY shall provide INGENEX during normal business hours reasonable access
to and shall permit INGENEX to make reasonable numbers of copies of the Records
for such purposes as INGENEX may reasonably request from time to time.  Any
copies or other activities undertaken by a party pursuant to this Section 4.14
shall be done at such party's sole cost and expense.

    4.15 POST-CLOSING ACCESS TO CERTAIN PERSONNEL. For a period of up to twelve
(12) months following the Closing Date, PPD and SUBSIDIARY shall permit INGENEX
to use the services of certain technical personnel of SUBSIDIARY upon providing
reasonable advance notice to, and obtaining the consent of, an officer of
SUBSIDIARY.  Such services shall not relate to the GSX System or the Business
and shall not interfere in any manner with SUBSIDIARY's operation of its
business.   In consideration for any services provided hereunder, INGENEX shall
pay to SUBSIDIARY fees based upon an effective hourly rate of  $75.00.  Such
fees shall be paid within fifteen (15) business days after receipt of an invoice
therefor.  Notwithstanding the foregoing, SUBSIDIARY agrees that Mark E. Furth,
Ph.D., and such other personnel of SUBSIDIARY as he may designate, shall
prepare, on behalf of INGENEX, certain due diligence reports required under the
License Agreements without payment of any amount therefor by INGENEX to
SUBSIDIARY or any other party.

                                      ARTICLE 5
                      REPRESENTATIONS AND WARRANTIES OF INGENEX

    In order to induce PPD and SUBSIDIARY to consummate the transactions
referred to in this Agreement, INGENEX represents, warrants and covenants to and
with PPD and SUBSIDIARY as follows:

    5.1  ORGANIZATION AND GOOD STANDING.  INGENEX is a corporation which is
duly organized and validly existing and in good standing under the laws of the
State of Delaware, and has the requisite power and authority to own, license or
lease the Acquired Assets and to conduct its business as now conducted.  INGENEX
is duly qualified to do business and is in good standing as a foreign
corporation in each jurisdiction where the character of the properties it owns,
licenses or leases or the nature of its business makes such qualification
necessary except where the failure to so qualify would not have a material
adverse effect on the Business.  SCHEDULE 5.1 lists all the states where INGENEX
is so qualified.  

    5.2   POWER AND AUTHORITY.  INGENEX has full right, power and authority to
enter into this Agreement and each of the Transaction Documents (as hereinafter
defined) to which it is a party and to perform its obligations under this
Agreement and the Transaction Documents.  The execution and delivery of this
Agreement and the Transaction Documents and the performance by INGENEX of its
obligations hereunder and thereunder have been duly authorized by all requisite
corporate action, and no further action or approval is required in order that
this Agreement shall be binding upon it and enforceable against it in accordance
with its terms, subject only to bankruptcy, insolvency, reorganization,
moratorium and other laws or equitable principles affecting creditors' rights
generally.  INGENEX represents and warrants that no


                                          8

<PAGE>

approval of the shareholders of INGENEX is required by Delaware Law, its
Certificate of Incorporation or Bylaws in connection with the consummation of
the transactions contemplated by this Agreement.  For purposes of this
Agreement, "Transaction Documents" means each of the agreements, documents and
instruments referenced in this Agreement to be executed and delivered by
INGENEX, PPD and/or SUBSIDIARY, as appropriate.

    5.3  LITIGATION.  There are no actions, suits, proceedings or
investigations pending or, to the knowledge of INGENEX, threatened, at law or in
equity, before or by any foreign, federal, state, municipal or other
governmental instrumentality which involve any judgment or liability, against
INGENEX, in each case as it relates to the Business, or which may result in any
material adverse change in the Business or the Acquired Assets.  INGENEX is not,
with respect to the Business, subject to or in violation of any order, writ,
injunction or decree of any court or foreign, federal, state, municipal or other
governmental department, commission, board, bureau or instrumentality.

    5.4  COMPLIANCE WITH CONTRACTS. INGENEX has delivered to SUBSIDIARY true
and complete copies of the Contracts and the License Agreements, together with
all amendments and supplements thereto and modifications thereof. Each of the
License Agreements, each of the Contracts and the Lease is valid, in full force
and effect and binding upon INGENEX and, to the knowledge of INGENEX, all other
parties thereto in accordance with its terms.  INGENEX is not in default under,
nor to the knowledge of INGENEX has any event occurred which, with a lapse of
time or notice or both, could result in a default under any of the Contracts,
the License Agreements, the Lease or under any outstanding note, indenture,
mortgage, instrument, contract or agreement relating to the Business to which
INGENEX is a party or by which the Premises or the Acquired Assets are bound,
except as disclosed in SCHEDULE 5.4.  INGENEX is not and will not be at Closing
in violation of any provision of its Certificate of Incorporation or Bylaws. 
The execution, delivery and performance of this Agreement, except as disclosed
in SCHEDULE 5.4, and the Transaction Documents and consummation of the
transactions contemplated hereby and thereby will not (i) violate, conflict with
or result in a breach of or constitute a default (or an event which, with notice
or lapse of time or both, would constitute a default) under the Contracts, the
License Agreements, the Lease or any outstanding note, indenture, mortgage,
instrument, contract or agreement relating to the Business to which INGENEX is a
party or by which the Premises or the Acquired Assets are bound, (ii) result in
the creation of any lien, security interest, charge or encumbrance upon or have
a material adverse effect on the Acquired Assets or the Premises, or (iii)
violate any of the terms, conditions or provisions of the Certificate of
Incorporation or Bylaws of INGENEX.  INGENEX has not received any advance
payments or other consideration with respect to any of the Contracts relating to
services which have not been or will not be performed prior to the Closing.

    5.5  COMPLIANCE WITH LAWS.  INGENEX conducts the Business in compliance
with all laws, statutes, regulations, rules, ordinances or orders applicable to
INGENEX or to the operation of the Business except where the failure to so
comply would not have a material adverse effect on the Business.  The execution,
delivery and performance of this Agreement and the Transaction Documents and
consummation of the transactions contemplated hereby and thereby will not result
in the termination, modification or acceleration of any order, writ, injunction,
decree, or any statute, rule or regulation, applicable to the Business, the
Acquired Assets or the Premises.


                                          9
<PAGE>

    5.6  TAX RETURNS AND TAXES. INGENEX will have filed on or before the
Closing Date or shall file on a timely basis with all appropriate governmental
agencies (whether foreign, federal, state or local) all returns required to be
filed by it with respect to Taxes, all of which will have been prepared
accurately and in conformity with all laws and regulations applicable thereto.
To INGENEX'S knowledge, no Tax returns of INGENEX have been examined or are
under examination by any foreign, federal, state or local agency with
examination responsibility thereover for the fiscal years presently open under
applicable statutes of limitation, and no assessments or deficiencies for such
fiscal years of INGENEX have been made or are now owning.  There are in effect
no waivers of the applicable statutes of limitation for Taxes for any period. 
There are in effect no agreements for an extension of time with respect to the
filing of any Tax return of INGENEX.

    5.7  FINANCIAL STATEMENTS.  Prior to Closing INGENEX shall deliver to PPD
and SUBSIDIARY audited balance sheets, income statements, and statements of
retained earnings and cash flows for the fiscal years ending December 31, 1994,
December 31, 1995 and December 31, 1996.  Said statements, together with an
unaudited interim balance sheet (the "Balance Sheet") and related statements of
income for the period ended March 31, 1997 are collectively hereinafter called
the "Financial Statements".  Each of the Financial Statements shall be in
accordance with the books and records of INGENEX and taken as a whole present
fully and fairly the financial position of INGENEX at the dates indicated, and
the results of operations for the periods indicated, and (except for the March
31, 1997 Financial Statements) have been prepared in accordance with generally
accepted accounting principles, consistently applied. 

    5.8  ABSENCE OF UNDISCLOSED LIABILITIES.  There are no debts, liabilities
or obligations either accrued, absolute, contingent or otherwise with respect to
the Business except (i) those arising in the ordinary course of business, and
(ii) those which are incurred in accordance with this Agreement.

    5.9  PERMITS, LICENSES AND CONSENTS.  Attached hereto as SCHEDULE 5.9 is a
list of: (i) all material governmental permits, licenses, registrations,
approvals and other authorizations that to the best of the knowledge of INGENEX
are required for the operation of the Business as presently operated and that if
not obtained would have a material adverse effect on the Business (the
"Permits"), and (ii) governmental and non-governmental third-party consents
which INGENEX knows are required to consummate fully the transactions
contemplated by this Agreement.  All such Permits are valid and outstanding,
INGENEX has duly complied, in all material respects, with all of the terms and
conditions of each Permit held by it, and no Permit has ever been revoked,
canceled or suspended or the subject of any investigation or proceeding for the
suspension, revocation or cancellation thereof.  INGENEX will use its best
efforts to determine which filings are required to be made and which consents
are required to be obtained prior to the Closing Date in connection with the
execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby and to timely file such filings and to timely
obtain all such consents.

    5.10 TITLE TO ACQUIRED ASSETS.  On the Closing Date, INGENEX will own and
have good title to all of the Acquired Assets (including without limitation the
Lease and the leasehold improvements on the Premises), free and clear of any
Liens and Encumbrances other than the Accepted Liens and Encumbrances.


                                          10

<PAGE>

    5.11 CONDITION OF ACQUIRED ASSETS.  Except as disclosed on SCHEDULE 5.11
all Equipment and Inventory of INGENEX and all pieces of equipment listed on
SCHEDULE 4.4 are currently operational, free and clear of known defects, and are
suitable for use in the manner in which they are currently employed in the
Business, and on the Closing Date shall be in the same condition as on the date
of this Agreement, normal wear and tear excepted. 

    5.12 USE OF PREMISES.  INGENEX has no knowledge of any condition on the
Premises which would unreasonably interfere with the use of the Premises by
SUBSIDIARY in the conduct of the Business.  To the knowledge of INGENEX, there
are no zoning restrictions or other restrictions upon the use of the Premises,
which, either individually or in the aggregate, adversely affect the use or
construction of the Premises and improvements located thereon as presently used
or constructed.   To the knowledge of INGENEX, none of the Premises and
improvements located thereon, or the use, occupancy, operation or maintenance
thereof, or any substance, material or condition thereon, is in violation of any
restriction, covenant, or laws (including, without limitation, any building,
zoning, health, fire, safety or other ordinance, code or regulation) the
violation of which would have a material adverse effect on the Business, the
Premises or the Acquired Assets.  No notice has been served upon INGENEX or upon
the Premises claiming violation of any restriction, covenant, or laws
(including, without limitation, any building, zoning, health, fire, safety or
other ordinance, code or regulation), or requiring or calling attention to the
need for any work, repairs, construction, alterations, or installation in
connection with the Premises or improvements thereon or claiming any monies due
with respect thereto.

    5.13 LEASE.  INGENEX has delivered to SUBSIDIARY true and complete copies
of the Lease, together with all amendments and supplements thereto and
modifications thereof.  The Lease is valid and effective and enforceable by
INGENEX in accordance with its terms.  INGENEX has the right of quiet enjoyment
of all property leased to it under the Lease for the full term of the Lease and
any renewal options thereto (provided such renewal options, if any, are properly
exercised), and, to the knowledge of INGENEX, no leasehold interest of INGENEX
under the Lease is subject to or subordinate to any security interest, lease,
encumbrance or other burden, except as set forth on SCHEDULE 5.13.  There is no
material default (or event which, with the passage of time or notice, would
constitute a material default) or claim of material default known by INGENEX to
be pending or asserted against INGENEX by any party to the Lease. INGENEX
further represents to SUBSIDIARY that INGENEX has no ownership of any real
estate or leasehold interest in real estate other than the Lease.

    5.14 LICENSE AGREEMENTS.  Except as set forth in SCHEDULE 5.14, INGENEX
represents, warrants and covenants that:

         5.14.1    The License Agreements are currently subsisting and have not
been adjudged invalid or unenforceable by any court or tribunal. Each of the
License Agreements is valid and enforceable and INGENEX is not aware of any
claim by any third party that any of the License Agreements is invalid or
unenforceable.

         5.14.2    Subject to the rights reserved under the License Agreements,
INGENEX is the sole and exclusive owner of the right, title and interest in and
to the License Agreements free and clear of any Liens and Encumbrances other
than the Accepted Liens and Encumbrances.


                                          11

<PAGE>

         5.14.3    All licenses and other agreements applicable to the License
Agreements are the valid and binding obligations of all of the parties thereto
and are enforceable against each of such parties in accordance with their
respective terms; provided that, with respect to any such parties other than
INGENEX, such representation and warranty is made to the knowledge of INGENEX. 
INGENEX has not entered into, and will not enter into prior to the Closing, any
currently subsisting or future license agreements with respect to any of the
License Agreements without PPD's prior written consent.

         5.14.4    Subject to the rights reserved under the License Agreements,
INGENEX has and shall continue to have through the Closing the exclusive right
to make, sell, practice and use all the inventions set forth in License
Agreements (other than uses by others pursuant to agreements set forth in
SCHEDULE 5.14 hereto) throughout the countries of issue, free and clear of any
and all Liens and Encumbrances or other restrictions on INGENEX's right to
protect or enforce any of the License Agreements against any third party.

         5.14.5    No effective financing statement, security agreement,
assignment, license or transfer or notice of any of the foregoing or of any lien
covering any of  the License Agreements is on file or record in any office or
agency of any foreign country or any intergovernmental organization, or any
other governmental or regulatory authority, agency or recording office, and
INGENEX has no knowledge of any such filing.

         5.14.6    No claim has been made to INGENEX that either the License
Agreements or INGENEX's use, sale or practice thereof does or may violate the
rights of any third party.  There has been no decision adverse to INGENEX's
claim of exclusive ownership rights (subject to the rights reserved under the
License Agreements) in the License Agreements or exclusive rights to use, sell
and practice the License Agreements in the United States (and all possessions
and territories thereof) or, to the knowledge of INGENEX, after good faith
inquiry with the appropriate officers and  legal counsel of INGENEX without
further investigation, in any other country or to keep and maintain the License
Agreements in full force and effect and no proceeding involving said rights is
to the knowledge of INGENEX, after good faith inquiry with the appropriate
officers and legal counsel of INGENEX without further investigation, threatened
or pending before or in any patent or similar office or agency of the United
States, of any state or foreign country, or of any intergovernmental
organization, or in any court or tribunal.

         5.14.7    To the knowledge of INGENEX, after good faith inquiry with
the appropriate officers and  legal counsel of INGENEX without further
investigation, there is no event which does or reasonably could materially
adversely affect the value of any of the License Agreements, or its ability to
transfer any of the License Agreements, or the rights and remedies of INGENEX in
relation to any of the License Agreements.

         5.14.8    INGENEX has at all times in the past used all statutory and
other appropriate symbols, notices or legends of ownership of the patents
licensed under the License Agreements, except where the failure to so use would
not have a material adverse effect on the material rights available with respect
to the License Agreements under all applicable laws.

         5.14.9    INGENEX has not and will not prior to the Closing abandon or
dedicate to the public any of the patents licensed under the License Agreements,
or do any act of a character that tends to cause or contribute to the
abandonment or dedication to the public of any of the patents



                                          12

<PAGE>

licensed under the License Agreements, or do or omit to do any act of a
character that tends to negate, hinder, prevent, restrain or retard such
abandonment, dedication to the public, loss, or other adverse effect.

         5.14.10  To the knowledge of INGENEX, after good faith inquiry with
the appropriate officers and  legal counsel of INGENEX without further
investigation, there is at present no material infringement or unauthorized or
other improper use of the patents or rights licensed under the License
Agreements inconsistent with INGENEX's rights in the License Agreements.

         5.14.11  INGENEX has secured from all consultants to and employees of 
INGENEX who contributed in a material manner to the creation or development of
any proprietary or potentially valuable rights related to the License Agreements
thereunder valid written assignments of the rights to such contributions that
are material to the Business of INGENEX and which INGENEX does not already own
by operation of law (subject to the limitations set forth in any such consulting
agreements).

    5.15 INTELLECTUAL PROPERTY.  With respect to the Intellectual Property and
except as set forth on SCHEDULE 5.15, INGENEX represents, warrants and covenants
that:

         5.15.1    INGENEX owns or is licensed or otherwise possesses legally
enforceable rights to use all the Intellectual Property that is used in the
Business as currently conducted by INGENEX.  

         5.15.2    To the knowledge of INGENEX, there is no material
unauthorized use, disclosure, infringement or misappropriation by any third
party (including employees and former employees of INGENEX) of any of the
Intellectual Property rights. INGENEX has not entered into any agreement to
indemnify any other person against any charge of infringement of any the
Intellectual Property, other than standard indemnification provisions contained
in contracts arising in the ordinary course of business and in the License
Agreements.

         5.15.3    To the knowledge of INGENEX:  (i) all patents, registered
trademarks, service marks and copyrights which are included in the Intellectual
Property and held by INGENEX are valid and subsisting, and (ii) the marketing,
licensing or sale of the Intellectual Property does not infringe any patent,
trademark, service mark, copyright, trade secret or other proprietary right of
any third party.  INGENEX has not brought any action, suit or proceeding for
infringement of the Intellectual Property or breach of any license or agreement
involving the Intellectual Property against any third party.

         5.15.4    INGENEX has secured from all consultants to and employees of
INGENEX who contributed in a material manner to the creation or development of
the Intellectual Property valid written assignments of the rights to such
contributions that are material to the Business of INGENEX and which INGENEX
does not already own by operation of law (subject to the limitations set forth
in any such consulting agreements).

         5.15.5    All use, disclosure or lawful appropriation of any of the
Intellectual Property owned by INGENEX and licensed to a third party has been
pursuant to the terms of a written agreement between INGENEX and such third
party. All use, disclosure or lawful


                                          13

<PAGE>

appropriation of the Intellectual Property not owned by INGENEX and licensed
from a third party has been pursuant to the terms of a written agreement between
INGENEX and the owner of the Intellectual Property, or is otherwise lawful.

    5.16 SUFFICIENCY OF ASSETS.  The Acquired Assets constitute all of the
assets and properties used by INGENEX in the Business during the past six (6)
months, except for Inventory which has been consumed or has been disposed of in
the ordinary course of business.  There is no significant asset used or required
by INGENEX in the conduct of the Business (as heretofore conducted) which is not
either owned by INGENEX or licensed or leased to it and listed in one of the
Schedules attached hereto.

    5.17 PENSION PLANS.  Each of the Retirement Plans (as hereinafter defined)
has been operated in all material respects in conformity with applicable plan
documents, the Code, applicable regulations thereunder and ERISA and has met all
reporting requirements thereunder in all material respects. "Retirement Plans"
means any employee pension benefit plan (including, without limitation, any
multi-employer pension plan) as defined in Section 3(2) of ERISA or under any
other state or federal statute regulating pension plans which INGENEX has
maintained, participated in or made contributions to on behalf of any of its
employees.

    5.18 CAFETERIA AND WELFARE BENEFIT PLANS.  Each program operated by INGENEX
and purporting to provide for the exclusion from income by INGENEX's employees
of amounts pursuant to Code Section 125 (and each other program relating
thereto) has been operated in all material respects in conformity with
applicable plan documents, the Code, applicable regulations thereunder and ERISA
and has met all reporting requirements thereunder in all material respects.  All
"employee welfare benefit plans" (as such term is defined in ERISA) heretofore
operated by INGENEX or any Related Party have been operated in all material
respects in conformity with applicable plan documents, the Code, applicable
regulations thereunder and ERISA and has met all reporting requirements
thereunder.

    5.19 LABOR RELATIONS.  The employees of INGENEX have not in the past and
are not presently represented by a union or any other agent or representative
and INGENEX is not a party to a collective bargaining agreement with its
employees.  There have been no attempts by a union or other representative to
organize the employees of INGENEX.

    5.20 EMPLOYMENT MATTERS.  SCHEDULE 5.20 attached hereto sets forth for the
employees of INGENEX identified on SCHEDULE 4.3, the names, positions, dates of
hire, and weekly salaries or hourly wages, of such employees as of the date
hereof, together with the dates of their last pay increases and the amount of
bonuses and description of agreements or arrangements for commissions and other
compensation or benefits to be paid or provided to any of such persons
including, without limitation vacation, sick leave, medical, dental, health
insurance or other similar plans or arrangements, Internal Revenue Service
qualified or otherwise maintained or provided by INGENEX and covering or
applying to any or all of such employees.

    5.21 ENVIRONMENTAL CONDITION OF PREMISES; COMPLIANCE WITH ENVIRONMENTAL
LAWS. INGENEX has no knowledge that INGENEX has released or disposed of
petroleum products or any toxic or hazardous waste or substance on the Premises.
INGENEX has been at all times in compliance with all applicable federal, state
or local laws, codes and ordinances and all rules and regulations promulgated
thereunder (collectively "Environmental Laws") regarding (i) the use,


                                          14
<PAGE>

generation, or disposal of "toxic or hazardous substances or wastes" (intended
hereby and hereafter to include any and all "toxic" or "hazardous materials" or
"hazardous wastes" as defined in applicable Environmental Laws) and petroleum
products (including crude oil or any fraction thereof) regardless of the
intended use of such petroleum products and regardless of whether defined by any
law to be a toxic or hazardous substance or waste; (ii) the transportation of
toxic or hazardous substances or wastes provided by any suppliers of INGENEX for
use in its operations (and for which transportation INGENEX is or has been
legally responsible under applicable Environmental Laws); (iii) the storage of
such toxic or hazardous substances or wastes on-site or off-site prior to their
use or processing; (iv) the storage of toxic or hazardous substances or wastes
generated by INGENEX in the course of such use or processing, and the
transportation of toxic or hazardous substances or wastes to the ultimate site
of their disposal except in each case, where the failure to so comply would not
have a material adverse effect on the Business. All, if any, arrangements with
third parties regarding disposal, or the transportation for disposal, of toxic
or hazardous substances or wastes of INGENEX have been made in conformity with
all applicable Environmental Laws except where the failure to so conform would
not have a material adverse effect on the Business.

    5.22 NO BROKERS.  No broker, finder, agent or other person claiming to have
acted in any such capacity for or under the authority of INGENEX is entitled to
any fee or commission arising out of the transactions contemplated herein.   

    5.23 INSURANCE.  There is presently in force fire, theft and general
casualty insurance covering the Acquired Assets and the Premises for their full
insurable value and INGENEX shall maintain such insurance in force until the
Closing Date.

    5.24 NO FALSE OR MISLEADING STATEMENTS.  No representation or warranty
relating to INGENEX contained in this Agreement, nor any certificate furnished
or to be furnished by INGENEX pursuant to this Agreement when taken or read
together as a whole, contains or shall contain any untrue statement of a
material fact or omits or will omit to state a material fact necessary to make
any representation or warranty contained herein, in light of the circumstances
under which made,  not misleading.  All Schedules and updates thereto have been
and are true, correct and complete.

                                      ARTICLE 6
                 REPRESENTATIONS AND WARRANTIES OF PPD AND SUBSIDIARY

    In order to induce INGENEX to consummate the transactions referred to in
this Agreement, each of PPD and SUBSIDIARY, jointly and severally, represents,
warrants and covenants to and with INGENEX as follows:

    6.1  ORGANIZATION AND GOOD STANDING.  Each of PPD and SUBSIDIARY is a
corporation duly constituted, validly existing and in good standing under the
laws of the State of North Carolina and has the requisite power and authority to
own, license or lease its assets and properties and conduct its business as now
conducted.

    6.2  POWER AND AUTHORITY.  PPD and SUBSIDIARY each has full right, power
and authority to enter into this Agreement and each of the Transaction


                                          15

<PAGE>

Documents to which it is a party and to perform their respective obligations 
under this Agreement and the Transaction Documents.  The execution and delivery
of this Agreement and the Transaction Documents to which PPD or SUBSIDIARY is a
party and the performance by each of them of their respective obligations
hereunder and thereunder have been duly authorized by their respective boards of
directors, and no further action or approval is required in order that this
Agreement and the Transaction Documents shall be binding upon each of them and
enforceable against each of them in accordance with its terms, subject only to
bankruptcy, insolvency, reorganization, moratorium and other laws or equitable
principles affecting creditors' rights generally.

    6.3  COMPLIANCE WITH CONTRACTS. The execution, delivery and performance of
this Agreement and the Transaction Documents and consummation of the
transactions contemplated hereby and thereby will not (i) violate, conflict with
or result in a breach of or constitute a default (or an event which, with notice
or lapse of time or both, would constitute a default) under any outstanding
note, indenture, mortgage, instrument, contract or agreement to which either PPD
or SUBSIDIARY is a party or by which either of them or their respective assets
are bound, or (ii) violate any of the terms, conditions or provisions of the
Articles of Incorporation or Bylaws of PPD or SUBSIDIARY.

    6.4  NO BROKERS.  No broker, finder, agent or other person claiming to have
acted in any such capacity for or under the authority of PPD or SUBSIDIARY is
entitled to any fee or commission arising out of the transactions contemplated
herein other than professional fees for the attorneys and accountants
representing PPD or SUBSIDIARY, which professional fees shall be paid solely by
PPD or SUBSIDIARY.

    6.5  NO FALSE OR MISLEADING STATEMENTS.  No representation or warranty
relating to PPD or SUBSIDIARY contained in this Agreement, nor any certificate
furnished or to be furnished by PPD or SUBSIDIARY pursuant to this Agreement,
when taken or read together as a whole, contains or shall contain any untrue
statement of a material fact or omits or will omit to state a material fact
necessary to make any representation or warranty contained herein, in light of
the circumstances under which made, not misleading. All Schedules and updates
thereto have been and are true, correct and complete.

                                      ARTICLE 7
                           PRE-CLOSING COVENANTS OF INGENEX

    From and after the date of this Agreement and continuing through and to the
Closing Date, INGENEX shall use its good faith business efforts to:

    7.1  CONDUCT OF BUSINESS.  Carry on the Business in the ordinary course and
in substantially the same manner and with like standards as heretofore
maintained.

    7.2  MAINTAIN RELATIONSHIPS.  Maintain INGENEX's current relationships with
its collaborative scientific partners, customers and suppliers as they relate to
the Business.

    7.3  COOPERATION. Cooperate fully with PPD and its employees or agents in
order to complete all investigations of INGENEX and the Business prior to the
Closing Date.


                                          16

<PAGE>

    7.4  LIMITATIONS ON DISTRIBUTIONS. Not make any distributions or payments
of the Acquired Assets (or any interests therein) to any of INGENEX's
shareholders or employees, except as required to consummate the transactions
contemplated hereunder.

    7.5  COMPLIANCE WITH LAWS.  Comply in all material respects with all
applicable foreign, federal, state and local laws, ordinances, rules and
regulations as they relate to the Business.

    7.6  ENVIRONMENTAL PROBLEMS.  Inform PPD or SUBSIDIARY of any known escape,
seepage, leakage, spillage, discharge, emission or release of any toxic or
hazardous substance or waste on the Premises or any other condition or event
which occurs in violation of any Environmental Laws.

    7.7  ACCESS TO PREMISES.  Permit PPD, its authorized agents and
representatives, access to the Records and the personnel of INGENEX and to the
Premises during normal business hours and in a manner that will not unreasonably
interfere with the Business operations of INGENEX for the purpose of conducting
due diligence and verifying the existence and condition of the Acquired Assets.

    7.8  LIMITATION ON EXPENDITURES.  Not make any expenditures or enter into
any contract or agreement relating to the Acquired Assets, the Assumed
Liabilities or the Business exceeding $25,000, except in the normal course of
business or as otherwise required to consummate the transactions contemplated
hereunder.

    7.9  USE OF ACQUIRED ASSETS.  Not use the Acquired Assets to be conveyed
hereunder, or any replacements thereof and additions thereto, other than in the
usual and ordinary course of business.
 
    7.10 NO DISPOSITION OF ACQUIRED ASSETS.  Not license, sell, mortgage, lease
or otherwise convey any of the Acquired Assets (or any interest therein) or
enter into any contract to effect the same except in the ordinary course of
business.

    7.11 OTHER ACTION. Not take any action, or fail to take any action, or do
anything which would in any way have a material adverse effect on the Business
or the Acquired Assets or terminate, impair or cancel the License Agreements or
the Lease.

                                      ARTICLE 8
                   CONDITIONS TO OBLIGATIONS OF PPD AND SUBSIDIARY

    The obligations of PPD and SUBSIDIARY under this Agreement are subject to
the satisfaction, or the waiver thereof by PPD and SUBSIDIARY, of the following
express conditions precedent on or before the Closing Date:

    8.1  CORRECTNESS OF WARRANTIES.  All of the representations and warranties
of INGENEX contained in this Agreement or the Transaction Documents were true
and correct when made and shall be true and correct at and as of the Closing
Date (except such representations, warranties and matters which are specifically
limited by reference to an earlier date and were true and correct as of such
earlier date).


                                          17

<PAGE>

    8.2  PERFORMANCE OF OBLIGATIONS.  INGENEX has performed and complied with
all of the obligations, covenants and conditions required to be performed or
complied in all material respects with by it at or prior to the Closing.

    8.3  NO ADVERSE CHANGE.  There shall have been no material adverse change
in the Acquired Assets or the Business.

    8.4  THIRD PARTY CONSENTS.  PPD and SUBSIDIARY shall have been furnished
with evidence satisfactory to it of the consent or approval of those persons
whose consent or approval shall be required to effect the transfer of the
Acquired Assets and the assumption of the Assumed Liabilities and to consummate
the transactions contemplated by this Agreement.

    8.5  GOVERNMENTAL APPROVAL. PPD and SUBSIDIARY shall have been furnished
with all governmental authority or agency approvals, waivers, authorizations and
consents necessary for consummation of or in connection with the transactions
contemplated by this Agreement.

    8.6  SATISFACTION OF LIENS AND ENCUMBRANCES.  All obligations with respect
to which any Lien or Encumbrance (other than the Accepted Liens and
Encumbrances) against any of the Acquired Assets may have existed shall have
been satisfied in full.

    8.7  NO LITIGATION OR PROCEEDINGS.  No litigation, proceedings, lawsuit or
investigations shall have been commenced with respect to any or all of the
Acquired Assets, the Premises and/or the Business, which may be reasonably
expected to result in a material adverse change thereto if decided adversely,
nor shall any party seek to enjoin, prevent or alter any material performance
under this Agreement or to prevent the Closing.

    8.8  DOCUMENTS TO BE DELIVERED BY INGENEX.  In addition to any other
documents or records required to be delivered hereunder, INGENEX shall deliver
or cause to be delivered to PPD or SUBSIDIARY at Closing (or as otherwise
provided for herein):

         8.8.1     A certified copy of the resolutions adopted by the board of
directors of INGENEX approving and authorizing the execution and delivery of
this Agreement and the consummation of the transactions contemplated herein.

         8.8.2     The Bill of Sale and Assignment in the form of EXHIBIT 1.2A.

         8.8.3     An Assignment and Assumption of License Agreements, in the
form of EXHIBIT 1.2B.

         8.8.4     An Assignment and Assumption of Contracts in the form of
EXHIBIT 1.2C.

         8.8.5     An Assignment of Patents and Patent Applications in the form
attached hereto as EXHIBIT 1.2D.

         8.8.6     The Intellectual Property Assignment in the form of EXHIBIT
1.2E.


                                          18

<PAGE>

         8.8.7     The Assignment, Assumption and Amendment of Lease in the
form of EXHIBIT 1.2F, including the consent of the landlord to the assignment of
the Lease.

         8.8.8     The Employment Agreements in the form of EXHIBITS 4.1A and
4.1B.

         8.8.9 Amendments to the Consulting Agreements with each of Igor
Roninson, Ph.D., Richard L. Davidson, Ph.D. and Eli Gilboa, Ph.D. required
pursuant to Section 4.2 hereof.

         8.8.10  Termination of Consulting Agreement with  Andrei Gudkov, Ph.D.
pursuant to Section 4.2 hereof.

         8.8.11  The Consulting Agreements in the form of EXHIBITS 4.2A and
4.2B. 

         8.8.12  New Lease Agreement with Phoenix required pursuant to Section
4.4 hereof.

         8.8.13  Release of the equipment from each of the Master Equipment
Lease and the Sublease and Acknowledgment of Assignment required pursuant to
Section 4.4 hereof.

         8.8.14  Release of the GSE Exclusive License Agreement from the
License Assignment and License Agreement required pursuant to Section 4.6
hereof.

         8.8.15  Termination of each of the Employment Agreements with Mark E.
Furth, Ph.D. and Tatyana Holzmayer, Ph.D. required pursuant to Section 4.7
hereof.

         8.8.16  A release in the form of EXHIBIT 4.8 from INGENEX with respect
to the Proprietary Information and Inventions Agreement with each person set
forth in Section 4.8.

         8.8.17  The Non-Competition Agreement in the form of EXHIBIT 4.13.

         8.8.18  A Closing Certificate dated as of the Closing Date signed by
the Chief Executive Officer of INGENEX to the effect that the conditions set
forth in Sections 8.1 and 8.2 have been satisfied.  The certificates shall have
the effect of affirming the representations and warranties made by INGENEX on
and as of the Closing Date.

         8.8.19  Updated Schedules and Exhibits hereto to the extent such
updates are necessary to make same full, complete and correct as of the Closing
Date.

         8.8.20    A Severance Agreement in the form of EXHIBIT 8.8.20 to be
executed by INGENEX in respect of each person set forth in Section 4.3.

         8.8.21  Such other instruments, documents or certificates required by
this Agreement or as PPD or SUBSIDIARY or its counsel shall reasonably request.

                                      ARTICLE 9
                         CONDITIONS TO OBLIGATIONS OF INGENEX


                                          19

<PAGE>

    The obligations of INGENEX under this Agreement are subject to the
satisfaction, or the waiver thereof by INGENEX, of the following express
conditions precedent on or before the Closing Date:

    9.1  CORRECTNESS OF WARRANTIES.  All of the representations and warranties
of PPD and SUBSIDIARY contained in this Agreement or the Transaction Documents
were true and correct when made and shall be true and correct at and as of the
Closing Date (except such representations, warranties and matters which are
specifically limited by reference to an earlier date and were true and correct
as of such earlier date).

    9.2  PERFORMANCE OF OBLIGATIONS. PPD or SUBSIDIARY has performed and
complied with all of the obligations, covenants and conditions required to be
performed or complied in all material respects with by it at or prior to the
Closing.

    9.3  THIRD PARTY CONSENTS.  INGENEX shall have timely obtained each consent
or approval of those persons whose consent or approval shall be required to
effect the transfer of the Acquired Assets and the assumption of the Assumed
Liabilities and to consummate the transactions contemplated by this Agreement.

    9.4  GOVERNMENTAL APPROVAL. INGENEX shall have timely obtained from each
governmental authority or agency all approvals, waivers, authorizations and
consents,  necessary for consummation of or in connection with the transactions
contemplated by this Agreement.

    9.5  NO LITIGATION OR PROCEEDINGS.  No litigation, proceedings, lawsuit or
investigations shall have been commenced with respect to any or all of the
Acquired Assets, the Premises and/or the Business, which may be reasonably
expected to result in a material adverse change thereto if decided adversely,
nor shall any party seek to enjoin, prevent or alter any material performance
under this Agreement or to prevent Closing.

    9.6  DOCUMENTS TO BE DELIVERED BY PPD or SUBSIDIARY.  In addition to any
other documents or records required to be delivered hereunder, PPD or SUBSIDIARY
shall deliver or cause to be delivered to INGENEX at Closing (or as otherwise
provided for herein):

         9.6.1     The Purchase Price in accordance with Section 2.1 and the
security deposit in accordance with Section 4.11. 

         9.6.2     A certified copy of the resolutions adopted by the board of
directors of PPD and SUBSIDIARY approving and authorizing the execution and
delivery of this Agreement and the consummation of the transactions contemplated
herein.

         9.6.3     An Assignment and Assumption of License Agreements in the
form of EXHIBIT 1.2B.

         9.6.4     An Assignment and Assumption of Contracts in the form of
EXHIBIT 1.2C.

         9.6.5     The Intellectual Property Assignment in the form of EXHIBIT
1.2E.


                                          20

<PAGE>

         9.6.6     The Assignment, Assumption and Amendment of Lease in the
form of EXHIBIT 1.2F, including any necessary guaranty by PPD and release of
TITAN as contemplated by Section 4.5 hereof.

         9.6.7     The Employment Agreements in the form of EXHIBITS 4.1A and
4.1B. 

         9.6.8     The Consulting Agreements in the form of EXHIBITS 4.2A and
4.2B. 

         9.6.9     New Lease Agreement with Phoenix required pursuant to
Section 4.4 hereof.

         9.6.10    A Closing Certificate dated as of the Closing Date signed by
the president or chief executive officer of each of PPD and SUBSIDIARY to the
effect that the conditions set forth in Sections 9.1 and 9.2 have been
satisfied.  The certificates shall have the effect of affirming the
representations and warranties made by PPD and SUBSIDIARY on and as of the
Closing Date.

         9.6.11  Such other instruments, documents or certificates required by
this Agreement or as INGENEX or its counsel shall reasonably request.

                                      ARTICLE 10
                                   INDEMNIFICATION

    10.1 INDEMNIFICATION OBLIGATION OF INGENEX.  From and after the Closing,
INGENEX shall reimburse, indemnify and hold harmless PPD and SUBSIDIARY, their
respective shareholders, officers, directors, employees, agents, successors and
assigns, from and against any and all claims, causes of action, judgments,
awards, demands, damages, losses, settlement payments, deficiencies,
liabilities, costs and expenses, including, without limitation, reasonable
attorneys' fees and court costs (hereinafter collectively referred to as
"Losses") suffered, sustained, incurred or required to be paid by PPD or
SUBSIDIARY that result from, relate to or arise out of:

         10.1.1    Any  breach of, or the failure to fulfill or perform,  any
representation or warranty, or the failure to fulfill or perform in any material
respect any agreement or covenant, of INGENEX contained in this Agreement or
contained in any certificate furnished to PPD or SUBSIDIARY by INGENEX in
connection with this Agreement;

         10.1.2    The failure by INGENEX to comply fully with the provisions
of the "bulk sales laws" of any jurisdiction, or governmental authority or
agency, to the extent applicable to the transactions contemplated by this
Agreement; or 

         10.1.3    The business, operations or assets of INGENEX other than as
relates to the operation of the Business, the Acquired Assets and the GSX System
on and after the Closing Date.

    10.2 LIMITATION ON INDEMNIFICATION OBLIGATION OF INGENEX.  Except as
otherwise provided in Section 10.8 of this Agreement, the indemnification
obligations of INGENEX in respect of any Losses of PPD and SUBSIDIARY shall be
limited to Five Million Dollars


                                          21

<PAGE>

($5,000,000) in the aggregate.  Further, INGENEX shall have no obligation to
indemnify PPD and SUBSIDIARY in respect of any Losses resulting from
circumstances described in Section 10.1 of this Agreement until the aggregate
amount of such Losses exceeds Seventy-Five Thousand Dollars ($75,000), and then
INGENEX shall be liable for the full extent of all such Losses (including those
less than Seventy-Five Thousand Dollars ($75,000)).

    10.3 INDEMNIFICATION OBLIGATION OF PPD AND SUBSIDIARY.  From and after the
Closing, PPD and SUBSIDIARY shall reimburse, indemnify and hold harmless INGENEX
and its shareholders, officers, directors, employees, agents, successors and
assigns, from and against any and all Losses suffered, sustained, incurred or
required to be paid by INGENEX that result from, relate to or arise out of:

         10.3.1    Any breach of, or the failure to fulfill or perform, any
representation or warranty, or the failure to fulfill or perform in any material
respect any agreement or covenant, of PPD or SUBSIDIARY contained in this
Agreement or contained in any certificate or other writing furnished to INGENEX
by or on behalf of PPD or SUBSIDIARY in connection herewith; 

         10.3.2    The failure of PPD or SUBSIDIARY to discharge the Assumed
Liabilities in accordance with their terms and the terms of this Agreement; or 

         10.3.3  The operation of the Business, the Acquired Assets and the GSX
System on and after the Closing Date.
 .
    10.4 SURVIVAL OF REPRESENTATIONS AND WARRANTIES.  The representations and
warranties given or made by INGENEX, PPD or SUBSIDIARY in this Agreement or in
any certificate or other writing furnished pursuant hereto shall survive the
Closing for a period of twelve (12)  months after the date hereof and shall
thereafter terminate and be of no further force or effect, except that (i) all
representations and warranties relating to Taxes of INGENEX shall survive the
Closing for the period of the applicable statute of limitations plus any
extensions or waivers thereof, and (ii) any representation or warranty as to
which a claim shall have been asserted during the survival period shall continue
in effect with respect to such claim until such claim shall have been finally
resolved or settled.  Notwithstanding any investigation or audit conducted
before or after the date hereof or the decision of any party to complete the
Closing, each party shall be entitled to rely upon the representations and
warranties of the other party set forth herein; provided, however, to the extent
that a party discovers that a representation or warranty made by the other party
is inaccurate and intentionally fails to disclose the same, the discovering
party shall lose its right to indemnification with respect to the inaccuracy of
any such representation or warranty.

    10.5 MANNER OF INDEMNIFICATION.  All Losses shall be paid promptly in cash
by the party responsible to provide indemnification hereunder (the "Indemnitor")
upon demand by the party entitled to indemnification hereunder (the
"Indemnitee").  Any claim for indemnification hereunder shall set forth in
reasonable detail the basis for such claim and the amount of Losses in respect
of which indemnification is being sought and a certification by the Indemnitee
that such claim is based upon a reasonable investigation and assessment of such
claim by the Indemnitee.

    10.6 REQUIREMENT FOR NOTICE.  In the event that any claim is asserted or
any action, suit or proceeding is commenced against an Indemnitee which can
reasonably be expected to result in


                                          22

<PAGE>

any liability or indemnity being imposed on an Indemnitor, the Indemnitee shall
exercise due diligence and reasonable judgment in defending or settling same and
shall give notice thereof to the Indemnitor in writing within a reasonable time
following the assertion of the claim or commencement of the action, suit or
proceeding (but the failure or delay to give any such notice shall not relieve
the Indemnitor of any liability on account thereof except to the extent the
Indemnitor was materially prejudiced thereby).  The Indemnitor shall have the
opportunity to participate in (but not control) the defense against such claim,
action, suit or proceeding and to participate in any negotiations with respect
thereto.  The Indemnitee shall have control of any defense or settlement, except
that the Indemnitor shall have the right at any time to assume and prosecute the
defense or claim and to assume control of the defense or settlement in the event
it admits in writing its liability to the Indemnitee hereunder with respect to
such matter and provides adequate security to assure its payment of such
liability to the Indemnitee.

    10.7 OTHER RIGHTS AND REMEDIES NOT AFFECTED.  Subject to the limitations
set forth in this Article 10, the indemnification rights of any party under this
Article 10 are independent of and in addition to such rights and remedies as
such party may have in equity for any misrepresentation, breach of warranty or
failure to fulfill any agreement or covenant hereunder on the part of INGENEX,
PPD or SUBSIDIARY.

    10.8 REPURCHASE RIGHTS.  In the event that PPD and SUBSIDIARY gives written
notice of demand for payment of indemnification obligations required to be paid
by INGENEX to PPD and SUBSIDIARY under Section 10.1 which, when added to
indemnification obligations already paid by INGENEX to PPD or SUBSIDIARY under
Section 10.1, exceed in the aggregate Three Million Dollars ($3,000,000), then
in such case INGENEX shall have right to repurchase (the "Repurchase
Transaction") the Acquired Assets, and any improvements made or developed in
respect of the Acquired Assets since the Closing Date, if and to the extent
still owned by SUBSIDIARY. INGENEX shall exercise its rights to repurchase the
Acquired Assets hereunder by giving written notice to PPD and SUBSIDIARY of its
intent to do so within thirty (30) days after final resolution of and written
notice to INGENEX of demand for payment of indemnification claims required to be
paid to PPD and SUBSIDIARY which, in the aggregate when added with all prior
indemnification claims paid by INGENEX, exceed Three Million Dollars
($3,000,000).  The closing of the Repurchase Transaction shall occur within
sixty (60) days after INGENEX's notice of its intention to exercise its right of
repurchase hereunder.  In the event INGENEX exercises its right of repurchase,
the purchase price for the Acquired Assets shall be Eight Million Seven Hundred
Twenty-Two Thousand Five Hundred Dollars ($8,722,500) adjusted as follows: (i)
less all amounts actually paid by INGENEX for indemnification obligations to PPD
and SUBSIDIARY in respect of any Losses, (ii) less the fair market value,
determined by independent appraisal at the time of sale, of any portion of the
Acquired Assets sold by SUBSIDIARY after the Closing Date, and (iii) plus
Twenty-Seven Thousand Two Hundred Twelve and 40/100 Dollars ($27,212.40) for
SUBSIDIARY's security deposit with the landlord under the Lease.  The purchase
price shall be paid in cash or other immediately available funds to SUBSIDIARY
at the closing of the Repurchase Transaction.  In addition to payment of the
purchase price, INGENEX shall effective as of the closing of the Repurchase
Transaction:  (i) assume, indemnify, defend and hold harmless PPD and SUBSIDIARY
from and against all of the Assumed Liabilities to the extent related to
performance due on or after the closing of the Repurchase Transaction, and (ii)
reimburse, indemnify and hold harmless PPD and SUBSIDIARY, their respective
shareholders, officers, directors, employees, agents, successors and assigns in
respect of any and all Losses of PPD and SUBSIDIARY without application of any
of the dollar limitations set forth in Section 10.2 above and without


                                          23

<PAGE>

application of the time limit set forth in Section 10.4 above.  Effective as of
the closing of the Repurchase Transaction, SUBSIDIARY shall convey the Acquired
Assets still owned by it to INGENEX and shall warrant to INGENEX that, since the
Closing Date, SUBSIDIARY has done nothing to impair title to such Acquired
Assets as SUBSIDIARY received it.  INGENEX shall be responsible for obtaining
any necessary governmental and third party consents to effect the Repurchase
Transaction and for negotiating and obtaining any employment and consulting
agreements it desires in connection with the Repurchase Transaction.  SUBSIDIARY
and PPD agree to provide INGENEX with any all information of which either has
knowledge in the same format, based upon the same investigation as conducted by
INGENEX, in which said information was provided to SUBSIDIARY and PPD by INGENEX
(but not with any representation or warranty of any sort by PPD or SUBSIDIARY)
with respect to the matters covered in Sections 5.3, 5.4, 5.5, 5.9, 5.10, 5.14
and 5.15 of this Agreement.

                                      ARTICLE 11
                               MISCELLANEOUS PROVISIONS

    11.1 NOTICES.  Any notice or other communication required or which may be
given hereunder shall be in writing and shall be deemed duly given when
delivered in person, or three (3) days after when mailed by certified (with the
sender's receipt postmarked by a postal employee) or registered mail (in either
case, with a copy by ordinary first-class mail) or one (1)-day after when mailed
by next-day express mail, or when sent by Federal Express or similar overnight
delivery service company, postage or express charges prepaid, in a securely
wrapped envelope addressed to the intended recipient as follows:

         11.1.1    If to INGENEX:

                          c/o Titan Pharmaceuticals, Inc.
                          Attn:  President
                          400 Oyster Point Boulevard, Suite G
                          South San Francisco, CA 94080-1921
                          Telephone: (415) 244-4990
                          Facsimile: (415) 244-4991
                   
                          With a copy to:

                          Charles I. Weissman, Esq.
                          Shereff, Friedman, Hoffman & Goodman, LLP
                          919 Third Avenue
                          New York, NY 10022-9998
                          Telephone (212) 758-9500
                          Facsimile (212) 758-9526


                                          24

<PAGE>

         11.1.2    If to SUBSIDIARY or PPD:

                          Fred N. Eshelman, Chief Executive Officer
                          Fred B. Davenport, Jr., General Counsel 
                          Pharmaceutical Product Development, Inc.
                          3151 17th Street Extension
                          Wilmington, NC  28412
                          Telephone:  (910) 251-0081
                          Facsimile:   (910) 772-6951
                   
                   With a copy to:
                   
                          G. Stephen Diab, Esq. 
                          Murchison, Taylor, Kendrick & Gibson, L.L.P.
                          16 North Fifth Avenue
                          Wilmington, NC 28401-4593  
                          Telephone:  (910) 763-2426
                          Facsimile:  (910) 763-6561

The designation of the person to be so notified or the address of such person
for the purposes of such notice may be changed from time to time by notice
hereunder.

    11.2 PARTIES IN INTEREST.  This Agreement shall be binding upon and inure
to the benefit of the parties hereto and their respective permitted successors
and assigns, but shall not be assigned by any party without the written consent
of the other party hereto (which consent may be withheld in the sole discretion
of such other party).  This Agreement shall not be for the benefit of or be
enforceable by any person, firm or entity other than PPD, SUBSIDIARY or INGENEX,
their permitted successors and assigns, and there are no third party
beneficiaries hereof.

    11.3 ENTIRE AGREEMENT.  This Agreement along with the schedules and
exhibits attached hereto and to be attached hereto at Closing sets forth all of
the promises, covenants, agreements, conditions and understandings among
SUBSIDIARY, INGENEX and PPD with respect to the subject matter hereof, and
supersedes all prior and contemporaneous agreements and understandings,
inducements or conditions, express or implied, oral or written, with respect
hereto, except as contained herein.

    11.4 AMENDMENT AND WAIVER.  This Agreement shall not be amended, modified,
altered or rescinded, or any rights hereunder waived, except by written
agreement signed by the parties hereto.  Moreover, no waiver by any party of any
right or condition, or of the breach of any term, covenant, representation or
warranty contained in this Agreement, in any one or more instances shall be
deemed or construed as a further or continuing waiver of any such condition or
breach or a waiver of any other condition or of the breach of any other term,
covenant, representation or warranty set forth in this Agreement. 

    11.5 SCHEDULES AND EXHIBITS.  Concurrently with the execution of this
Agreement, the parties have attached to this Agreement certain schedules and
exhibits referred to herein, which


                                          25

<PAGE>

schedules and exhibits are hereby made a part hereof by reference thereto. 
Certain schedules shall be attached hereto after the execution hereof, or
updated as of Closing and shall be true, accurate and complete as of the date of
attachment.

    11.6 CONTROLLING LAW.  The parties hereto acknowledge that, notwithstanding
that this Agreement or any counterpart hereof may be executed and consummated
elsewhere, this Agreement shall be governed by and construed and enforced in
accordance with the laws of the State of North Carolina.

    11.7 CAPTIONS.  The captions of the various sections, subsections and
clauses are solely for the convenience of the parties hereto and shall not
control or affect the meaning or construction of this Agreement.

    11.8 COUNTERPARTS.  This Agreement may be executed in one or more
counterparts, each of which shall constitute an original agreement but all of
which together shall constitute one and the same instrument.

    11.9 SEVERABILITY.  If any term or provision of this Agreement is found by
a court of competent jurisdiction to be invalid or unenforceable, in whole or in
part, then the rest and remainder of this Agreement, and such provisions or term
in other situations, shall remain valid and enforceable to the fullest extent
permitted by law, and to that end this Agreement shall be severable.

    11.10     RELEASE OF INFORMATION.  Neither party shall make any public
announcement regarding this Agreement before Closing without the other party's
prior consent.  PPD and/or TITAN shall have the right to make public
announcements regarding this Agreement at such times as it determines, in good
faith and in its sole discretion, disclosure is required by applicable
securities laws or NASDAQ National Market rules.  Any other public announcements
regarding this Agreement shall be made by PPD and INGENEX at a mutually
acceptable date and time.  Nothing contained herein shall prevent either party
at any time from promptly furnishing any information required by any
governmental authority or (in the case of PPD or TITAN) the NASDAQ National
Market rules.

    11.11     COSTS.  Each party shall bear its own costs of professional and
other consulting fees related to this transaction.


                                          26

<PAGE>

    IN WITNESS WHEREOF, the parties hereto have executed this Agreement,
individually or through their duly authorized officers, and affixed their seals
hereto, all as of the day and year first above written.


[CORPORATE SEAL]                       PHARMACEUTICAL PRODUCT
                                       DEVELOPMENT, INC.


ATTEST:                      BY:       /s/ Frederic N. Eshelman
                                       ------------------------
-------------------------              NAME: FREDERIC N. ESHELMAN
---------------Secretary               TITLE: CHIEF EXECUTIVE OFFICER


[CORPORATE SEAL]                       SUBSIDIARY NO. 3, INC.


ATTEST:                      BY:       /s/ Frederic N. Eshelman
                                       ------------------------
-------------------------              NAME: FREDERIC N. ESHELMAN
---------------Secretary               TITLE: PRESIDENT



[CORPORATE SEAL]                       INGENEX, INC.


ATTEST:                      BY:       /s/ Mark E. Furth
                                       -----------------
-------------------------              NAME: MARK E. FURTH
---------------Secretary               TITLE: PRESIDENT


                                          27